Best Adrenal Cancer Hospital in Hyderabad — 11 Centres, NCCN Protocols, NABH-Accredited Partners

No single hospital is automatically best — and for adrenal cancer (which is extremely rare), the most important factors are whether the hospital has a surgical team experienced specifically with adrenal surgery, an endocrinologist co-leading the workup, and the discipline to perform complete hormonal testing before any treatment. CION Cancer Clinics meets these criteria with 11 centres across Hyderabad and 1,000+ adrenal cancer cases managed every year.

Verify eight things in writing: an endocrine surgery or surgical oncology team with adrenal experience and an endocrinologist co-lead, multidisciplinary review with hormonal workup before treatment, annual adrenal surgery volume, complete hormonal workup with dedicated CT adrenal imaging and functional imaging, pre-operative hormonal management (especially alpha-blockade for pheochromocytoma), NABH-accredited partners for adrenalectomy, insurance and ArogyaSri empanelment, and lifelong hormone management plus genetic counselling where relevant.

No — and this is one of the most important early facts to understand. Adrenal nodules are surprisingly common on imaging done for other reasons (called 'adrenal incidentalomas'), and most of them are benign adenomas that don't need any treatment. Some adrenal tumours are pheochromocytomas, which produce excess adrenaline-like hormones; most pheochromocytomas are benign but they need careful surgical management to be safe. Adrenocortical carcinoma — true adrenal cancer — is rare (about 1–2 cases per million annually). And many adrenal nodules found on scans are actually metastases from cancer elsewhere (lung, breast, kidney, melanoma). The key to good adrenal care is proper workup before any treatment: hormone tests and dedicated imaging to determine exactly what kind of adrenal tumour is present.

Outcomes depend on which kind of adrenal tumour. For adrenocortical carcinoma (true adrenal cancer), per US National Cancer Institute SEER data, 5-year relative survival is approximately 70% for localised disease, 40% for regional spread, and 10–20% for distant spread, with an overall average of around 50%. For pheochromocytoma, most benign forms are essentially cured by complete surgical removal; malignant pheochromocytomas have 5-year survival of approximately 30–50%. For adrenal incidentalomas confirmed as benign on workup, no treatment is needed. The hospital you choose has a disproportionately large effect on outcomes for adrenal cancer because experienced adrenal surgery and proper hormonal management are critical.

Costs vary by tumour type and treatment complexity. Indicative ranges: complete hormonal workup ₹15,000–30,000; CT adrenal protocol ₹6,000–12,000; MIBG scan for pheochromocytoma ₹15,000–30,000; laparoscopic adrenalectomy ₹2.5–5 lakh; open adrenalectomy with possible multi-organ resection ₹4–8 lakh via NABH-accredited partner; mitotane therapy for adrenocortical carcinoma ₹50,000–1 lakh per month (chronic); EDP-M chemotherapy for advanced ACC ₹1–2 lakh per cycle; genetic testing ₹15,000–30,000; lifelong hormone replacement after bilateral adrenalectomy is relatively modest in ongoing cost. CION provides a written treatment plan and itemised cost estimate before treatment begins, with an EMI facility available on selected packages.

Adrenal cancer is unusual because the workup and management cross between surgical oncology and endocrinology. A cancer-specialty hospital or network with a partner pathway for adrenal surgery, combined with an endocrinologist co-leading the workup, offers the multidisciplinary structure this rare condition needs. A multi-specialty general hospital with both in-house endocrinology and adrenal surgery experience can also work well. The structural fit for most patients is the cancer-specialty pathway with NABH-accredited partners for surgery and integrated endocrinology workup. The single most important thing to verify is whether the surgical team has documented adrenal surgery experience — not just general surgical oncology.

This is counterintuitive but important. For most adrenal tumours suspected of being cancer, needle biopsy before surgery is avoided for two reasons. First, biopsy of a suspected adrenocortical carcinoma can spread cancer cells along the needle path. Second, and more dangerous, biopsy of an undiagnosed pheochromocytoma can trigger a sudden, dangerous release of adrenaline-like hormones, causing severe blood pressure spikes that can be life-threatening. This is why the standard approach is complete hormonal workup first (which would identify a pheochromocytoma), dedicated imaging that gives a strong indication of the tumour type, and then surgical removal — which is both diagnostic and therapeutic. Biopsy is reserved for specific situations (mostly when metastatic disease from elsewhere is suspected) and only after appropriate hormonal evaluation.

Pheochromocytoma is a tumour that produces excess adrenaline-like hormones (catecholamines). During surgery, manipulating the tumour can cause sudden, massive releases of these hormones into the bloodstream, leading to dangerous blood pressure spikes that can cause stroke, heart attack, or death. To prevent this, every pheochromocytoma patient must be 'blocked' with specific medications (alpha-blockers) for 7–14 days before surgery — this is non-negotiable. The medications dilate blood vessels and stabilise the cardiovascular system to handle the hormone releases that occur during the operation. Hospitals with experience in pheochromocytoma surgery have established alpha-blockade protocols and anaesthetists trained specifically for these cases. A pheochromocytoma operated on without proper preparation is a serious safety risk.

Up to 25% of pheochromocytomas and related tumours called paragangliomas have a hereditary basis — meaning they're caused by an inherited gene change that can affect other family members. Genes involved include RET (causing multiple endocrine neoplasia type 2), VHL (von Hippel-Lindau syndrome), the SDH gene family, and NF1. Identifying a hereditary syndrome matters for the patient (different surveillance for other tumours), for siblings and children (who may carry the same gene and benefit from early screening), and sometimes for treatment decisions. Current guidelines recommend genetic counselling and testing for most patients diagnosed with pheochromocytoma, particularly younger patients, those with multiple or bilateral tumours, and those with a family history. CION coordinates genetic counselling as part of comprehensive adrenal care.

Many qualified hospitals are empanelled for ArogyaSri and most major cashless insurers — but empanelment varies by centre and by procedure. Adrenalectomy is generally covered. Mitotane and some genetic tests may have specific scheme rules. CION Cancer Clinics is empanelled for ArogyaSri and accepts most major cashless insurance providers and TPAs. Request a written cost estimate and confirm pre-authorisation before treatment begins, particularly for chronic mitotane therapy and lifelong hormone monitoring.